Zotek – 200
Symptomatic treatment of low and moderate intensity pain of different origin: toothache, back pain, joints, muscles, rheumatic pain, dysmenorrhea.
Non-steroidal anti-inflammatory and anti-rheumatic drugs. Derivatives of propionic acid. Dexibuprofen. ATX code M01A E14.
Dexibuprofen is a pharmacologically active isomer of racemic ibuprofen, which belongs to non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). Its mechanism of action is associated with inhibition of prostaglandin synthesis. The drug has antipyretic, analgesic and anti-inflammatory properties.
The results of comparative clinical trials in the treatment of osteoarthritis, dysmenorrhea, pain (including toothache) indicate that dexibuprofen at a dose 2 times lower than ibuprofen has similar effectiveness.
After oral administration, dexibuprofen is rapidly and completely absorbed from the small intestine. The maximum concentration in the blood is reached approximately 2 hours after oral administration of 200 mg of the drug. Plasma protein binding is approximately 99%.
Dexibuprofen is metabolized in the liver (hydroxylation, carboxylation), and then excreted as inactive metabolites, mainly (90%) by the kidneys, the rest – with bile. The half-life is 1.8-3.5 hours.
Symptomatic treatment of mild to moderate pain of various origins: toothache, back pain, joint pain, muscle pain, rheumatic pain, dysmenorrhea.
Hypersensitivity to dexibuprofen, other NSAIDs or to other components of the drug; use in patients in whom substances with a similar mechanism of action, such as acetylsalicylic acid and other NSAIDs, cause asthma attacks, bronchospasm, acute rhinitis or lead to the development of nasal polyps, urticaria or angioneurotic edema; history of bleeding or perforation of the gastrointestinal tract associated with NSAID use; active phase of peptic ulcer disease / bleeding in the digestive tract, peptic ulcer disease / bleeding in the digestive tract in the anamnesis (at least two confirmed facts of ulcer or bleeding); Crohn’s disease or nonspecific ulcerative colitis in the active phase; cerebrovascular bleeding or other bleeding in the active phase; hematopoietic disorders or blood clotting; severe hepatic failure, severe renal failure, severe heart failure.
Contact Us with any inquiries.